Results highlight specificity of TLR3-agonist TL-532, that induces lifelong anti-tumor auto-vaccination and reverses resistance to immune checkpoint inhibitors
Un produit très prometteur et une phase clinique prévue en 2024
AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of TL-532
These results confirm two new properties for TL-532, which showed proof-of-concept of inducing tumor cell death by apoptosis and reversing resistance to immune checkpoint inhibitors in previous studies.
Prof. Guido Kroemer’s team, from Gustave Roussy, will test Tollys’ specific TLR3 agonist, TL-532, to restore deficient chemotherapeutic responses in the context of FPR1 deficiency. FPR1 deficiency affects 30% of world population and is associated with precocious manifestation of breast, colorectal, esophageal, head and neck carcinomas.
Tollys accelerates development of TLR3 agonist candidates for intravenous administration in immuno-oncology
Based on the strong preclinical data collected to date with locally administered TL-532, Tollys is accelerating and expanding its internal and collaborative R&D activities on TLR3 agonist candidates designed for intravenous administration and antibody-drug-conjugates.
Nasser Azli is a medical oncologist with over 30 years of academic and pharmaceutical experience. As an expert in clinical oncology and drug development, Nasser Azli is a highly valuable addition to our Scientific Advisory Board, particularly in view of the upcoming first clinical trials of our drug candidate TL-532.